Top

Published in:

01-07-2018 | Case report

Pathologic complete response after gemcitabine and S-1 chemotherapy for far advanced intrahepatic cholangiocarcinoma

Authors: Takaaki Tatsuguchi, Kunihito Gotoh, Shogo Kobayashi, Kei Asukai, Akira Tomokuni, Hirofumi Akita, Hiroshi Wada, Hidenori Takahashi, Masayuki Ohue, Masahiko Yano, Masato Sakon

Published in: International Cancer Conference Journal | Issue 3/2018

Abstract

We report the case of a 72-year-old man who was initially diagnosed with far advanced intrahepatic cholangiocarcinoma, associated with bulky lymph node metastasis involving the common hepatic artery and moderate amount of ascites around the liver. After 10 cycles of systemic chemotherapy combining gemcitabine and S-1 with well-tolerated toxicities, a CT scan showed a marked shrinkage of the liver mass and lymph nodes (clinical partial response) with disappearance of ascites, which could permit a radical resection of the tumor. He underwent left lobectomy of the liver with lymph node dissection, and histopathological examination revealed pathologic complete response. Seven years after surgery, he is in a good overall condition.

Khan SA, Toledano MB, Taylor-Robinson SD et al (2008) Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 10:77–82CrossRef

Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33:1353–1357CrossRefPubMed

Khan SA, Thomas HC, Davidson BR et al (2005) Cholangiocarcinoma. Lancet 366(9493):1303–1314CrossRefPubMed

Lazaridis KN, Gores GJ (2005) Cholangiocarcinoma. Gastroenterology 128(6):1655–1667CrossRefPubMed

Murakami S, Ajiki T, Okazaki T et al (2014) Factors affecting survival after resection of intrahepatic cholangiocarcinoma. Surg Today 44:1847–1854CrossRefPubMed

Schlinker RT, Nagorney DM, Van Heerden JA et al (1992) Intrahepatic cholangiocarcinoma: clinical aspects, pathology and treatment. HPB Surg 5:95–101CrossRef

Weber SM, Jarnagin WR, Klimstra D et al (2001) Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 193:384–91CrossRefPubMed

Tajima Y, Kuroki T, Fukuda K et al (2004) An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br J Surg 91:99–104CrossRefPubMed

Yamashita Y, Taketomi A, Morita K et al (2008) The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: retrospective analysis of 60 patients. Anticancer Res 28(4C):2353–2359PubMed

10.

de Jong MC, Nathan H, Sotiropoulos GC et al (2011) Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 29(23):3140–3145CrossRefPubMed

11.

Uchiyama K, Yamamoto M, Yamaue H et al (2011) Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatibiliary Pancreat Sci 18(3):443–52CrossRef

12.

Inoue K, Makuuchi M, Takayama T et al (2000) Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 127(5):498–505CrossRefPubMed

13.

Choi SB, Kim KS, Choi JY et al (2009) The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 16(11):3048–3056CrossRefPubMed

14.

Li DY, Zhang HB, Yang N et al (2013) Routine lymph node dissection may be not suitable for all intrahepatic cholangiocarcinoma patients: results of a monocentric series. World J Gastroenterol 19(47):9084–9091CrossRefPubMedPubMedCentral

15.

Marubashi S, Gotoh K, Takahashi H et al (2014) Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): importance of preoperatively-determined anatomic invasion level and number of tumors. Dig Dis Sci 59(1):201–13CrossRef

16.

Yamamoto M, Takasaki K, Yoshikawa T (1999) Extended resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg 6(2): 117–21CrossRef

17.

Kobayashi S, Gotoh K, Takahashi H et al (2016) Clinicopathological features of surgically-resected biliary tract cancer following chemo-radiation therapy. Anticancer Res 36(1):335–42PubMed

18.

Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281CrossRefPubMed

19.

Nakamura K, Yamaguchi T, Ishihara T et al (2005) Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 92(12):2134–2139CrossRefPubMedPubMedCentral

20.

Sasaki T, Isayama H, Nakai Y et al (2010) Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 65(6):1101–1107CrossRefPubMed

21.

Kato A, Shimizu H, Ohtsuka M et al (2015) Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol 22:S1093-9CrossRefPubMed

22.

Slupski MW, Szczylik C, Jasinski MK (2007) Unexpected response to systemic chemotherapy in case of primary nonresectable advanced disseminated intrahepatic cholangiocarcinoma. World J Surg Oncol 5:36CrossRefPubMedPubMedCentral

23.

Tran TB, Bal CK, Schaberg K et al (2015) Locally advanced intrahepatic cholangiocarcinoma: complete pathologic response to neoadjuvant chemotherapy followed by left hepatic trisectionectomy and caudate lobectomy. Dig Dis Sci 60(11):3226–3229CrossRefPubMed

24.

Donahue JM, Nochols FC, Li Z et al (2009) Complete pathologic response after neoadjuvant chemotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 87(2):392–398CrossRefPubMedPubMedCentral

25.

Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE, Wolf R et al (2012) Pathological complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol 16(1):29–37CrossRefPubMed

26.

Zorcolo L, Rosman AS, Restivo A et al (2012) Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol 19(9):2822–2832CrossRefPubMed

Title: Pathologic complete response after gemcitabine and S-1 chemotherapy for far advanced intrahepatic cholangiocarcinoma
Authors: Takaaki Tatsuguchi
Kunihito Gotoh
Shogo Kobayashi
Kei Asukai
Akira Tomokuni
Hirofumi Akita
Hiroshi Wada
Hidenori Takahashi
Masayuki Ohue
Masahiko Yano
Masato Sakon
Publication date: 01-07-2018
Publisher: Springer Japan
Published in: International Cancer Conference Journal / Issue 3/2018
Electronic ISSN: 2192-3183
DOI: https://doi.org/10.1007/s13691-018-0327-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

A case of ureteral obstruction and sepsis induced by bladder perforation following intravesical bacillus Calmette–Guérin successfully treated with an antituberculous agent, antimicrobial chemotherapy and percutaneous urine drainage

A case of rapidly progressing prostate cancer diagnosed 20 months after holmium laser enucleation of the prostate

Endoscopic self-expandable metal stent placement for malignant afferent loop obstruction caused by peritoneal recurrence after total gastrectomy

A case of second primary lung cancer diagnosed by surgical resection at salvage setting

Guillain–Barré syndrome in a cancer patient treated with bevacizumab

Pyoderma gangrenosum after radical prostatectomy: case report

Keynote webinar | Spotlight on antibody–drug conjugates in cancer